The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism
Abstract
BACKGROUND Direct oral anticoagulants (DOACs) are an alternative to low-molecular-weight heparin for treating cancer-associated venous thromboembolism (VTE). RESEARCH QUESTION Is rivaroxaban as efficient and safe as dalteparin to treat patients with cancer-associated VTE? STUDY DESIGN AND METHODS In a randomized open-label non-inferiority trial, patients with active cancer who had proximal deep-vein thrombosis (DVT) and/or pulmonary embolism (PE) were randomly assigned to therapeutic doses of rivaroxaban or dalteparin for 3 months. The primary outcome was the cumulative incidence of recurrent VTE, a composite of symptomatic or incidental DVT or PE, and worsening of pulmonary vascular or venous obstruction at 3 months. RESULTS Of 158 randomized patients, 74 and 84 patients were assigned to receive rivaroxaban and dalteparin, respectively. Mean age was 69.4 years, 115 patients (76.2%) had metastatic disease. The primary outcome occurred in 4 and 6 patients in the rivaroxaban and dalteparin groups, respectively (cumulative incidence 6.4% vs 10.1%, subdistribution hazard ratio [SHR] 0.75, 95% confidence interval [CI] 0.21-2.66, in both the intention-to-treat and per-protocol populations). Major bleeding occurred in 1 and 3 patients in the rivaroxaban and dalteparin groups, respectively (cumulative incidence 1.4% vs 3.7%, SHR 0.36, 95%CI 0.04-3.43). Major or clinically relevant non-major bleeding occurred in 9 and 8 patients in the rivaroxaban and dalteparin groups, respectively (cumulative incidence 12.2% vs 9.8%, SHR 1.27, 95%CI 0.49-3.26). Overall, 19 (25.7%) and 20 (23.8%) patients died in the rivaroxaban and dalteparin groups, respectively (HR 1.05, 95% CI, 0.56-1.97). INTERPRETATION In this trial comparing rivaroxaban and dalteparin in the treatment of cancer-associated VTE, the number of patients was insufficient to reach the predefined criteria for non-inferiority, but efficacy and safety results were consistent with those previously reported with DOACs. An updated meta-analysis of randomized trials comparing DOACs with low-molecular-weight heparin in patients with cancer-associated VTE is provided. TRIAL REGISTRATION NCT02746185.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Büller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353
Cited by
Farge, D., Frere, C., Connors, J. M., Khorana, A. A., Kakkar, A., Ay, C., Muñoz, A., Brenner, B., Prata, P. H., Brilhante, D., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00160-7 · Cited by 486
Self-citationVenous thromboembolism in cancer patients: ESMO Clinical Practice Guideline
Falanga, A., Ay, C., Di Nisio, M., Gerotziafas, G., Jara-Palomares, L., Langer, F., Lecumberri, R., Mandala, M., Maraveyas, A., Pabinger, I., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.12.014 · Cited by 413
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update
Key, N. S., Khorana, A. A., Kuderer, N. M., Bohlke, K., Lee, A. Y. Y., Arcelus, J. I., Wong, S. L., Balaban, E. P., Flowers, C. R., Gates, L. E., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00294 · Cited by 363
Mechanisms and management of thrombosis in cancer: Focus on gastrointestinal malignancies
Monegatti, S., Martinelli, N., Friso, S., Spronk, H. M. H., & Cate, H. T. (2025) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.124.002203 · Cited by 10
Metadata
- Authors
- Planquette, B., Bertoletti, L., Charles-Nelson, A., Laporte, S., Grange, C., Mahé, I., Pernod, G., Elias, A., Couturaud, F., Falvo, N., Sevestre, M. A., Ray, V., Burnod, A., Brebion, N., Roy, P.-M., Timar-David, M., Aquilanti, S., Constans, J., Bura-Rivière, A., Brisot, D., Chatellier, G., Sanchez, O., Meyer, G., Girard, P., Mismetti, P., Meyer, G., Mismetti, P., Chatellier, G., Laporte, S., Decousus, H., Mahé, I., Falvo, N., Delluc, A., Bertoletti, L., Laneau, C., Dinut, A., Aegerter, P., Emmerich, J., Decousus, H., Girard, P., Messas, E., Revel, M.-P., Charles-Nelson, A., Laporte, S., Bertoletti, L., Acassat, S., Mismetti, P., Grange, C., Meyer, G., Planquette, B., Sanchez, O., Mahé, I., Plaisance, L., Poénou, G., Pernod, G., Imbert, B., Zenati, N., Couturaud, F., Le Moigne, E., Le Mao, R., Hoffmann, C., Elias, A., Elias, M., Falvo, N., Loffroy, R., Jandot, M., Sevestre, M.-A., Modéliar Rémond, S. S., Ray, V., Burnod, A., Roy, P.-M., Moumneh, T., Henni, S., Brebion, N., Timor-David, M., Constans, J., Boulon, C., Aquilanti, S., Brisot, D., Bura-Rivière, A., Bertoletti, L., Couturaud, F., Girard, P., Laporte, S., Mahé, I., Meyer, G., Mismetti, P., Planquette, B., & Sanchez, O.
- Venue
- Chest
- Publisher
- Elsevier BV
- Published
- 2022-03
- Volume
- 161
- Issue
- 3
- Pages
- 781-790
- ISSN
- 0012-3692 (ISSN-L)
- OpenAlex
- W3204114911
- Cited by
- 163
- References
- 2
- FWCI
- 21.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism. https://app.cochat.ai/papers/10.1016/j.chest.2021.09.037
- The paper
- Planquette, B., Bertoletti, L., Charles-Nelson, A., Laporte, S., Grange, C., Mahé, I., Pernod, G., Elias, A., Couturaud, F., Falvo, N., Sevestre, M. A., Ray, V., Burnod, A., Brebion, N., Roy, P.-M., Timar-David, M., Aquilanti, S., Constans, J., Bura-Rivière, A., . . . Sanchez, O. (2022). Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism. Chest. https://doi.org/10.1016/j.chest.2021.09.037
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.